Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
114M
-
Number of holders
-
235
-
Total 13F shares, excl. options
-
96.1M
-
Shares change
-
+69.9K
-
Total reported value, excl. options
-
$5.62B
-
Value change
-
+$808K
-
Put/Call ratio
-
0.48
-
Number of buys
-
113
-
Number of sells
-
-113
-
Price
-
$58.51
Significant Holders of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) as of Q4 2021
299 filings reported holding FATE - FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share as of Q4 2021.
FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) has 235 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 96.1M shares
of 114M outstanding shares and own 84.01% of the company stock.
Largest 10 shareholders include Redmile Group, LLC (13M shares), ARK Investment Management LLC (10.3M shares), VANGUARD GROUP INC (7.68M shares), BlackRock Inc. (7.06M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.93M shares), Bellevue Group AG (3.78M shares), Casdin Capital, LLC (3.4M shares), JOHNSON & JOHNSON (3.38M shares), Capital World Investors (3.26M shares), and STATE STREET CORP (2.72M shares).
This table shows the top 235 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.